Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2015 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2014 Net Income-$1.69M-$1.69MN/M vs Q3 2014 EPS Diluted$0.71$0.71N/M vs Q3 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flowderived-$633,000N/M ended Sep 30, 2015 · filed Nov 13, 2015 · 44 d after period end